Antibody Information

General Information of This Antibody
Antibody ID
ANI0APAKI
Antibody Name
Anti-CTLA4 mAb clone 9D9
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Murine IgG1-kappa
Antigen Name
Cytotoxic T-lymphocyte protein 4 (CTLA4)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
CTLA4-IR700 [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 38.00% Positive CTLA4 expression (CTLA4 +++/++)
Method Description
Mice with tumors reaching approximately 50-100 mm3 in volume were used for the experiments. Mice were monitored each day and tumor volume (length x width2 x 0.5) was measured twice a week until the tumor volume reached 2,000 mm3.
In Vivo Model Oropharyngeal cancer PDX model (PDX: mEERL-hEGFR)
References
Ref 1 Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Mol Cancer Ther. 2021 Nov;20(11):2262-2273. doi: 10.1158/1535-7163.MCT-21-0470. Epub 2021 Sep 13.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.